US Patent 9803029 Bispecific CD33 and CD3 binding proteins
Patent 9803029 was granted and assigned to Amphivena Therapeutics on October, 2017 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 9803029 Bispecific CD33 and CD3 binding proteins
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
